Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.

Published by腰 乐 Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies."— Presentation transcript:

1 Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Brain, Volume 142, Issue 4, 11 March 2019, Pages 1009–1023, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 NOTCH3 protein modifying rare and low frequency variants in the 3C-Dijon extreme SVD cohort. Figure 2 NOTCH3 protein modifying rare and low frequency variants in the 3C-Dijon extreme SVD cohort. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Brain, Volume 142, Issue 4, 11 March 2019, Pages 1009–1023, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 MRI images of participants carrying heterozygote genotypes at CADASIL and CARASIL causing mutations. (A) ... Figure 3 MRI images of participants carrying heterozygote genotypes at CADASIL and CARASIL causing mutations. (A) Baseline (1) and 4-year follow-up (2) MRI scans of a 65-year old female participant with extensive SVD, in whom a NOTCH3 EGFr domain cysteine-modifying mutation was found: NM_ (NOTCH3):c.C2353T:p.R785C. Images show lacunar infarcts and dilated perivascular spaces in basal ganglia and white matter, and WMH in the periventricular region and deep white matter; on the follow-up MRI scan WMH and dilated perivascular spaces burden had increased and WMH became visible in the anterior temporal lobes (yellow arrows), a typical location for CADASIL. This participant remained free of stroke and dementia until the end of her follow-up at age 77. Her MMSE score was 28 at baseline and 26 at 12 years follow-up (secondary school education but no high school). (B) Baseline MRI scan of a 74-year-old female participant with extensive SVD, in whom a heterozygous CARASIL causing mutation was found: NM_ (HTRA1):c.1108C > T (p.Arg370Ter). Images show WMH and lacunes in the pons and extensive WMH in the deep white matter and periventricular region (magenta arrows). This participant was free of stroke and dementia at baseline but was lost to follow-up. Her baseline MMSE score was 27 (primary school education). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Brain, Volume 142, Issue 4, 11 March 2019, Pages 1009–1023, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 3: Full-body skeletal scintigraphy.

Figure 3: Full-body skeletal scintigraphy.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1 Flowchart of our CIS cohort considering patients (A) and eyes (B) as statistical unit. Unless provided in the caption above, the following copyright.

Figure 1 Flowchart of our CIS cohort considering patients (A) and eyes (B) as statistical unit. Unless provided in the caption above, the following copyright.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

Similar presentations

Ads by Google